Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics
April 18, 2016Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology
Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
Roche sues Intas Pharma over patent dispute in India
April 18, 2016Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent
Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …
NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy
April 18, 2016Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation
Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …
Shire announces new $400 million biologics plant and 400 new jobs in Ireland
April 18, 2016Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals
Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Clinical trial initiated to help Paris attacks victims with PTSD
April 15, 2016Medical Communications, Research and Development France, clinical trial, mcgill, mcgill university, terror attacks
Victims of the recent Paris terror attacks have been offered the opportunity to take part in a clinical trial, organised …
Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
April 15, 2016Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
Pfizer fined for epilepsy drug price increase by UK antitrust regulator
April 15, 2016Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn
Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …
US annual spending on drugs rose 12.2% in 2015 – IMS
April 15, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending
The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer
April 15, 2016Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university
Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …
Synta Pharmaceuticals announces merger with Madrigal
April 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger
Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
Merck appoints Maya Martinez-Davis as global head of oncology
April 14, 2016Medical Communications Merck, maya martinez-davis, oncology
Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …
Merck says US FDA to review its Keytruda for head & neck cancer
April 14, 2016Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
Zika causes microcephaly and other birth defects, says CDC
April 14, 2016Medical Communications, Research and Development CDC, Zika, Zika virus, birth defects, microcephaly
The US Centers for Disease Control and Prevention has concluded that the Zika virus is a cause of microcephaly and …
Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
April 14, 2016Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
AbbVie announces positive Phase III results in hepatitis C drug
April 14, 2016Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III
AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …
NICE issues new guidance on the safer use of controlled drugs
April 13, 2016Medical Communications NICE, controlled drugs, guidance
The National Institute for Health and Care Excellence (NICE) has issued guidance bringing together legislation and existing advice on the …
Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
